Survey of Ophthalmology
Volume 44 , Pages S119-S129 , January 2000

Preclinical Overview of Brinzolamide

  • Louis DeSantis, PhD

      Affiliations

    • Alcon Research, Ltd., Fort Worth, TX, USA
    • Corresponding Author InformationReprint address: Louis DeSantis, PhD (R3-26), Vice President, Product Support, Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX 76134

References 

  1. Anderson DR. Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma. Surv Ophthalmol. 1999;43(suppl 1):S5–S9
  2. Barnes GE, Li B, Dean T, Chandler ML. Improvement of optic nerve head blood flow after one-week b.i.d. topical CAI treatment with brinzolamide in the rabbit. Surv Ophthalmol. 2000;44(suppl 2):S131–S140
  3. Barnes GE, Li B, Dean T, Chandler ML. Improvement of optic nerve head blood flow after one-week b.i.d. topical CAI treatment with brinzolamide in the rabbit (abstract). Invest Ophthalmol Vis Sci. 1998;39(suppl):S263
  4. Becker B. The effects of the carbonic anhydrase inhibitor, acetazolamide, on the composition of the aqueous humor. Am J Ophthalmol. 1955;40(part II):129–136
  5. Becker B. The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol. 1955;39:177–184
  6. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox (a preliminary report). Am J Ophthalmol. 1954;37:13–15
  7. Boriack-Sjodin PA, Zeitlin S, Chen HH, et al.  Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci. 1998;7:2483–2489
  8. Breinin GM, Gortz H. Carbonic anhydrase inhibitor acetazolamide (Diamox) (a new approach to the therapy of glaucoma). Arch Ophthalmol. 1954;52:333–338
  9. Camras CB, the Brinzolamide Primary Therapy Study Group . A triple-masked, primary therapy study of the efficacy and safety of bid and tid-dosed brinzolamide 1% compared to tid-dosed dorzolamide 2% and bid-dosed timolol 0.5% (abstract). Invest Ophthalmol Vis Sci. 1997;38:S560
  10. Chen RF, Kernohan JC. Combination of bovine carbonic anhydrase with a fluorescent sulfonamide. J Biol Chem. 1967;242:5813–5823
  11. Conroy CW, Schwam H, Maren TH, et al.  The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metab Dispos. 1984;12:614–618
  12. Creighton TE: Physical interactions that determine the properties of proteins, in Creighton TE (ed): Proteins. Structures and Molecular Properties. New York, W.H. Freeman & Co., 1993, ed 2, pp 157–60
  13. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93:232–237
  14. Dean T, May J, Chen HH, et al.  Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbits and cynomolgus monkey. Invest Ophthalmol Vis Sci. 1997;38(suppl):S813
  15. Donohue EK, Wilensky JT. Dorzolamide (a review). Semin Ophthalmol. 1997;12:119–126
  16. Eller MG, Schoenwald RD, Dixson JA, et al.  Topical carbonic anhydrase inhibitors, III (optimization model for corneal penetration of ethoxzolamide analogues). J Pharm Sci. 1985;74:155–160
  17. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects (serum chemical analysis). Arch Ophthalmol. 1977;95:1378–1382
  18. Friedenwald JS. The formation of the intraocular fluid (Proctor Award Lecture of the Association for Research in Ophthalmology). Am J Ophthalmol. 1949;32(part II):9–27
  19. Grant WM: Antiglaucoma drugs: problem with carbonic anhydrase inhibitors, in Leopold IH (ed): Symposium on Ocular Therapy. St Louis, CV Mosby, 1973, pp 19–38
  20. Grant WM, Trotter RR. Diamox (acetazolamide) in treatment of glaucoma. Arch Ophthalmol. 1954;51:735–739
  21. Hall R, Havner G, Baker J, et al: Brinzolamide, in Brittain HG (ed): Analytical Profiles of Drug Substances and Excipients, Vol. 26, San Diego, Academic Press, 1999, pp 47–96
  22. Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128:292–296
  23. Kinsey VE. Comparative chemistry of aqueous humor in posterior and anterior chambers of rabbit eyes. Arch Ophthalmol. 1953;50:401–417
  24. Kinsey VE, Reddy DVN. Turnover of carbon dioxide in the aqueous humor and the effect thereon of acetazolamide. Arch Ophthalmol. 1959;62:78–83
  25. Kupfer C, Gaasterland D, Ross K. Studies of aqueous humor dynamics in man, V (effects of acetazolamide and isoproterenol in young and old normal volunteers). Invest Ophthalmol. 1976;15:349–355
  26. Kupfer C, Gaasterland D, Ross K. Studies of aqueous humor dynamics in man, II (measurements in young normal subjects using acetazolamide and L-epinephrine). Invest Ophthalmol. 1971;10:523–533
  27. Leibman KC, Alford D, Boudet RA. Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961;131:271–274
  28. Linner E. The effect of pilocarpine and acetazolamide on the outflow resistance in normal and glaucomatous human eyes. Doc Ophthalmol. 1966;20:170–174
  29. Mann T, Keilin D. Sulfanilamide as a specific inhibitor of carbonic anhydrase. Nature. 1940;146:164–165
  30. Maren TH. The development of topical carbonic anhydrase inhibitors. J Glaucoma. 1995;4:49–62
  31. Maren TH, Godman DR, Pancorbo BM, Vogh BP. Timolol decreases aqueous humor flow but not Na+ movement from plasma to aqueous. Invest Ophthalmol Vis Sci. 1997;38:1274–1277
  32. Maren TH, Jankowska L, Sanyal G, Edelhauser HF. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res. 1983;36:457–479
  33. Maren TH, Wadsworth BC, Yale EK, Alonso LG. Carbonic anhydrase inhibition, III (effects of Diamox on electrolyte metabolism). Bull Johns Hopkins Hosp. 1954;95:277–321
  34. Maren TH, Wynns GC, Wistrand PJ. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme. Mol Pharmacol. 1993;44:901–905
  35. Matsui H, Murakami M, Wynns GC, et al.  Membrane carbonic anhydrase (IV) and ciliary epithelium (carbonic anhydrase activity is present in the basolateral membranes of the non-pigmented ciliary epithelium of rabbit eyes). Exp Eye Res. 1996;62:409–417
  36. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45–49
  37. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol. 1992;230:518–520
  38. Meldrum NU, Roughton FJW. Carbonic anhydrase (its preparation and properties). J Physiol. 1933;80:113–142
  39. Miller WH, Dessert AM, Roblin RO. Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J Am Chem Soc. 1950;72:4893–4896
  40. Ponticello GS, Freedman MB, Habecker CN, et al.  Thienothiopyran-2-sulfonamides (a novel class of water-soluble carbonic anhydrase inhibitors). J Med Chem. 1987;30:591–597
  41. Privalov PL, Gill SJ. Stability of protein structure and hydrophobic interaction. Adv Protein Chem. 1988;39:191–234
  42. Roblin RO, Clapp JW. The preparation of heterocyclic sulfonamides. J Am Chem Soc. 1950;72:4890–4892
  43. Rosenberg LF, Krupin T, Tang LQ, et al.  Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 1998;105:88–92[see comments]discussion 92–3
  44. Shin DH, the Brinzolamide Adjunctive Therapy Study Group . A triple-masked, placebo-controlled, adjunctive therapy study of the efficacy and safety of tid-dosed brinzolamide 1.0% compared to tid-dosed placebo when used adjunctively to timolol 0.5% (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl):S559
  45. Stams T, Chen Y, Boriack-Sjodin PA, et al.  Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide (molecular basis of isozyme-drug discrimination). Protein Sci. 1998;7:556–563
  46. Stewart R, the Brinzolamide Comfort Study Group . The ocular comfort of tid-dosed brinzolamide 1.0% compared to tid-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl):S559
  47. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315–1319
  48. Wayman L, Larsson LI, Maus T, et al.  Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:1368–1371[see comments]
  49. Wistrand PJ. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand. 1951;24:144–148
  50. Wistrand PJ, Garg LC. Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci. 1979;18:802–806
  51. Woltersdorf OW, Schwam H, Bicking JB, et al.  Topically active carbonic anhydrase inhibitors, 1 (O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide). J Med Chem. 1989;32:2486–2492

☆ The author is employed by Alcon Research, Ltd.

PII: S0039-6257(99)00108-3

Survey of Ophthalmology
Volume 44 , Pages S119-S129 , January 2000

Article Tools

* Image Usage & Resolution